South Korean OTC Maker Slammed for Multiple Issues

Drug Industry Daily
A A
The FDA issued a warning letter to a South Korean OTC manufacturer Dermameal for violations at its facility in Gyeonggi-do, including the incomplete quality testing and an inadequate stability program.

To View This Article:

Login

Subscribe To Drug Industry Daily